The role of SOFT and TEXT in treatment decision making for patients with breast cancer

HER2-Negative Breast Cancer | Beyond the Guidelines: Clinical Investigator Perspectives on the Ma...Подробнее

Session 9: Adjuvant endocrine therapy for premenopausal women: Risk stratification, type & durationПодробнее

Coordination of Care: A Breast Cancer Treatment DecisionПодробнее

Dr. Chagpar on the Role of Nurses in the Breast Cancer Decision-Making ProcessПодробнее

Decision-making Impact of the Breast Cancer IndexПодробнее

2022 West Oncology Conference | Breast Cancers | Early-StageПодробнее

Two trials, SOFT and TEXT, investigating combination treatments for patients with breast cancerПодробнее

SOFT & TEXT trialsПодробнее

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFTПодробнее

Dr. O’Shaughnessy on Clinical Implications of the TEXT and SOFT Trials in Breast CancerПодробнее

The Role of BCI in Extended Endocrine Therapy Decision MakingПодробнее

Role of Advanced Practitioners in Extended Endocrine Therapy Decision-Making (or BCI)Подробнее

Dr. O'Shaughnessy on Phosphoprotein Assays for Treatment Decision-Making for Breast CancerПодробнее

Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast CancerПодробнее

Dr. Rao on the SOFT Trial in Patients With Premenopausal Breast CancerПодробнее

TEXT and SOFT TrialsПодробнее

Determining Benefit of Ovarian Function Suppression: SOFT TrialПодробнее

Dr. Francis Discusses the SOFT Trial for Breast CancerПодробнее

Ovarian Suppression in Metastatic HR+ Breast CancerПодробнее

Adjuvant Therapy of Breast CancerПодробнее

JADPRO Live 2023 - Standardizing Extended Endocrine Therapy Decision-MakingПодробнее